Showing results (311-320 of 427) with videos related to
Sort By:
Pageof 43
American Journal of Hematology|October 5, 2016
Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patientsNicola Polverelli, Massimo Breccia, Giulia Benevolo, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 26, 2015
Catheter-associated bloodstream infections and thrombotic risk in hematologic patients with peripherally inserted central catheters (PICC)Salvatore Giacomo Morano, Roberto Latagliata, Corrado Girmenia, et al.Leukemia Research|February 1, 2015
Hemoglobin levels and circulating blasts are two easily evaluable diagnostic parameters highly predictive of leukemic transformation in primary myelofibrosisAngela Rago, Roberto Latagliata, Marco Montanaro, et al.Cancer|October 6, 2023
Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemiaFabio Efficace, Francesco Cottone, Betina Yanez, et al.Cancer|December 13, 2017
Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromesFabio Efficace, Francesco Cottone, Gregory Abel, et al.Journal of Clinical Medicine|May 14, 2022
Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical-Biological Entity?Alessia Campagna, Daniela De Benedittis, Luana Fianchi, et al.Journal of Clinical Medicine|February 10, 2024
e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular ResponseSílvia Marcé, Aleix Méndez, Blanca Xicoy, et al.British Journal of Haematology|September 14, 2024
Leucocytosis during induction therapy with all-trans-retinoic acid and arsenic trioxide in acute promyelocytic leukaemia predicts differentiation syndrome and treatment-related complicationsLaura Cicconi, Marialaura Bisegna, Carmelo Gurnari, et al.Blood|April 1, 2011
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working PartyGabriele Gugliotta, Fausto Castagnetti, Francesca Palandri, et al.European Journal of Haematology|May 5, 2020
Erythropoietin treatment in chronic phase chronic myeloid leukemia patients treated with frontline imatinib who developed late anemiaLaura Cesini, Camilla Frieri, Claudia Baratè, et al.Pageof 43